TRATTAMENTO CON 131-I METAIODOBENZILGUANIDINA IN BAMBINI AFFETTI DA NEUROBLASTOMA

Translated title of the contribution: 131-I-metaiodobenzylguanidine treatment in children with neuroblastoma

A. Garaventa, F. Claudiani, C. Pianca, P. Picco, M. Nigro, M. Conte, L. Bertolazzi, C. Pizzoccaro, G. Scopinaro, B. De Bernardi

Research output: Contribution to journalArticle

Abstract

This study reports our experience in metabolic radiotherapy in 54 children with advanced neuroblastoma treated between 1986 and 1992 with 131-I-metaiodobenzylguanidine (131-I MIBG). One child was treated at diagnosis, 8 for a primary tumor inoperable after chemotherapy, 20 children had been resistant to first line therapy, 4 had suffered a local relapse, 4 a disseminated relapse and 17 had suffered a disseminated relapse without overt bone infiltration. One child was treated initially because of resistance to first-line therapy, and subsequently for a local relapse. A total of 125 courses of 131-I MIBG was administered, with doses ranging from 2.6 to 6.0 GBq (median 3.7 GBq). One child received five courses, 3 four courses, 21 three courses, 13 two courses and 16 one course of 131-I MIBG. The most common toxic effect was thrombocytopenia. Seven children presented a reduced thyroideal function and 5 are presently receiving thyroxine. There were 9 major responses (two complete), and 7 minor responses. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated by chemotherapy where experienced disseminated relapse.

Original languageItalian
Pages (from-to)502-506
Number of pages5
JournalRivista Italiana di Pediatria
Volume19
Issue number5
Publication statusPublished - 1993

Fingerprint

Neuroblastoma
Recurrence
Therapeutics
Drug Therapy
Poisons
Residual Neoplasm
Thyroxine
Thrombocytopenia
Radiotherapy
Bone and Bones
Neoplasms

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

TRATTAMENTO CON 131-I METAIODOBENZILGUANIDINA IN BAMBINI AFFETTI DA NEUROBLASTOMA. / Garaventa, A.; Claudiani, F.; Pianca, C.; Picco, P.; Nigro, M.; Conte, M.; Bertolazzi, L.; Pizzoccaro, C.; Scopinaro, G.; De Bernardi, B.

In: Rivista Italiana di Pediatria, Vol. 19, No. 5, 1993, p. 502-506.

Research output: Contribution to journalArticle

Garaventa, A, Claudiani, F, Pianca, C, Picco, P, Nigro, M, Conte, M, Bertolazzi, L, Pizzoccaro, C, Scopinaro, G & De Bernardi, B 1993, 'TRATTAMENTO CON 131-I METAIODOBENZILGUANIDINA IN BAMBINI AFFETTI DA NEUROBLASTOMA', Rivista Italiana di Pediatria, vol. 19, no. 5, pp. 502-506.
Garaventa, A. ; Claudiani, F. ; Pianca, C. ; Picco, P. ; Nigro, M. ; Conte, M. ; Bertolazzi, L. ; Pizzoccaro, C. ; Scopinaro, G. ; De Bernardi, B. / TRATTAMENTO CON 131-I METAIODOBENZILGUANIDINA IN BAMBINI AFFETTI DA NEUROBLASTOMA. In: Rivista Italiana di Pediatria. 1993 ; Vol. 19, No. 5. pp. 502-506.
@article{5c4b1db418e74bbfb46a367f79eee73e,
title = "TRATTAMENTO CON 131-I METAIODOBENZILGUANIDINA IN BAMBINI AFFETTI DA NEUROBLASTOMA",
abstract = "This study reports our experience in metabolic radiotherapy in 54 children with advanced neuroblastoma treated between 1986 and 1992 with 131-I-metaiodobenzylguanidine (131-I MIBG). One child was treated at diagnosis, 8 for a primary tumor inoperable after chemotherapy, 20 children had been resistant to first line therapy, 4 had suffered a local relapse, 4 a disseminated relapse and 17 had suffered a disseminated relapse without overt bone infiltration. One child was treated initially because of resistance to first-line therapy, and subsequently for a local relapse. A total of 125 courses of 131-I MIBG was administered, with doses ranging from 2.6 to 6.0 GBq (median 3.7 GBq). One child received five courses, 3 four courses, 21 three courses, 13 two courses and 16 one course of 131-I MIBG. The most common toxic effect was thrombocytopenia. Seven children presented a reduced thyroideal function and 5 are presently receiving thyroxine. There were 9 major responses (two complete), and 7 minor responses. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated by chemotherapy where experienced disseminated relapse.",
keywords = "I-131 meta iodobenzylguanidine, neuroblastoma, therapy",
author = "A. Garaventa and F. Claudiani and C. Pianca and P. Picco and M. Nigro and M. Conte and L. Bertolazzi and C. Pizzoccaro and G. Scopinaro and {De Bernardi}, B.",
year = "1993",
language = "Italian",
volume = "19",
pages = "502--506",
journal = "Rivista Italiana di Pediatria",
issn = "0392-5161",
publisher = "Pacini Editore s.r.l.",
number = "5",

}

TY - JOUR

T1 - TRATTAMENTO CON 131-I METAIODOBENZILGUANIDINA IN BAMBINI AFFETTI DA NEUROBLASTOMA

AU - Garaventa, A.

AU - Claudiani, F.

AU - Pianca, C.

AU - Picco, P.

AU - Nigro, M.

AU - Conte, M.

AU - Bertolazzi, L.

AU - Pizzoccaro, C.

AU - Scopinaro, G.

AU - De Bernardi, B.

PY - 1993

Y1 - 1993

N2 - This study reports our experience in metabolic radiotherapy in 54 children with advanced neuroblastoma treated between 1986 and 1992 with 131-I-metaiodobenzylguanidine (131-I MIBG). One child was treated at diagnosis, 8 for a primary tumor inoperable after chemotherapy, 20 children had been resistant to first line therapy, 4 had suffered a local relapse, 4 a disseminated relapse and 17 had suffered a disseminated relapse without overt bone infiltration. One child was treated initially because of resistance to first-line therapy, and subsequently for a local relapse. A total of 125 courses of 131-I MIBG was administered, with doses ranging from 2.6 to 6.0 GBq (median 3.7 GBq). One child received five courses, 3 four courses, 21 three courses, 13 two courses and 16 one course of 131-I MIBG. The most common toxic effect was thrombocytopenia. Seven children presented a reduced thyroideal function and 5 are presently receiving thyroxine. There were 9 major responses (two complete), and 7 minor responses. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated by chemotherapy where experienced disseminated relapse.

AB - This study reports our experience in metabolic radiotherapy in 54 children with advanced neuroblastoma treated between 1986 and 1992 with 131-I-metaiodobenzylguanidine (131-I MIBG). One child was treated at diagnosis, 8 for a primary tumor inoperable after chemotherapy, 20 children had been resistant to first line therapy, 4 had suffered a local relapse, 4 a disseminated relapse and 17 had suffered a disseminated relapse without overt bone infiltration. One child was treated initially because of resistance to first-line therapy, and subsequently for a local relapse. A total of 125 courses of 131-I MIBG was administered, with doses ranging from 2.6 to 6.0 GBq (median 3.7 GBq). One child received five courses, 3 four courses, 21 three courses, 13 two courses and 16 one course of 131-I MIBG. The most common toxic effect was thrombocytopenia. Seven children presented a reduced thyroideal function and 5 are presently receiving thyroxine. There were 9 major responses (two complete), and 7 minor responses. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated by chemotherapy where experienced disseminated relapse.

KW - I-131 meta iodobenzylguanidine

KW - neuroblastoma

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=0027820488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027820488&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0027820488

VL - 19

SP - 502

EP - 506

JO - Rivista Italiana di Pediatria

JF - Rivista Italiana di Pediatria

SN - 0392-5161

IS - 5

ER -